Promising results from drug trials offer Alzheimer’s hope

LONDON: A drug that delivers copper to the brain has emerged as a potential treatment for Alzheimer’s after it was found to purge the brain of the toxic proteins believed to be behind the debilitating disease.

Monash University researchers are heralding the “promising” discovery after a five-year study showed the drug can improve long-term spatial memory, with the hope it can, ultimately, help reverse cognitive decline.

The groundbreaking research is in its early stages and yet to progress to human trials, but the copper-based drug is being touted as a much cheaper and easier treatment to access than other Alzheimer’s drugs currently on the market.

Alzheimer’s disease and other forms of dementia recently became Australia’s leading cause of death, overtaking coronary heart disease, with more than 17,500 deaths recorded in 2024.

The Monash University study, which was recently published in the journal ACS Chemical Neuroscience, found the copper compound repairs vital pumps in the brain that work like a “waste removal system”.

Lead author Jae Pyun, from the Monash Institute of Pharmaceutical Sciences, said in Alzheimer’s disease, toxic proteins start “building up” because the waste removal system in the brain stops working properly.

“Our recent study suggests that this copper-based drug can help switch that system back on,” Dr Pyun said.

“We’ve essentially found a new way … to have the brain clear toxic proteins by repairing its own waste removal system.”

If not repaired, the system is likened to a clogged drain that prevents toxic proteins from being flushed out through the bloodstream.

Dr Pyun said his team, who conducted various lab experiments using mice, is the first to use the copper-based drug to target this part of the brain for Alzheimer’s research.

His colleague Joseph Nicolazzo said the copper compound can quickly transition into human trials because it has already undergone safety evaluations for other diseases.

“These preclinical results strongly support the rationale for testing this drug in early symptomatic Alzheimer’s disease,” he said.

Dr Pyun also spoke of the “adrenaline rushing in” when he started to see that the drug was restoring the pumps in the brain, leading to a reduction in toxic proteins and improved cognitive function.

“By improving the pumps, the brain can finally clear out the trapped waste,” he said.

“Over 56 days, the treatment reduced toxic (proteins) by 42 per cent and improved spatial learning by nearly 44 per cent.”

Alzheimer’s disease is a type of dementia that affects a person’s memory, thinking and behaviour, with the symptoms worsening over time.

According to Alzheimer’s Research Australia, there are around 480,000 Australians living with all forms of dementia, with Alzheimer’s disease accounting for over 70 per cent of cases.

There are currently treatments that may slow the progress of Alzheimer’s disease, but there is no known cure.